LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...

--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ...

--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ® (maralixibat) for the ...

The Food and Drug Administration (FDA) has approved a tablet formulation of Livmarli ® (maralixibat).

Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...

Peter Radovich, president and chief operating officer at Mirum, highlighted the success of LIVMARLI since its launch and expressed optimism that the new tablet formulation will positively impact ...

Peter Radovich, president and chief operating officer at Mirum, highlighted the success of LIVMARLI since its launch and expressed optimism that the new tablet formulation will positively impact ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food ...

Riverbed, the leader in AIOps for observability, today announced that it has been selected as the winner of the ?Data Observability Solution Provider of the Year' award in the 6th annual Data ...